In the same vein as weather forecast models that predict developing storms, researchers now have developed a method to ...

Pharmaceutical giant Merck is buying Verona Pharma, a company that concentrates its efforts on respiratory diseases, in an approximately $10 billion deal.

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing therapies across oncology, immunology, and diabetes and cardiovascular areas ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the EXPrESSIVE Phase 3 clinical trials, evaluating ...

Jefferies has raised its price target on Merck & Co. (NYSE: MRK) to $141 from $138 while maintaining a Buy rating, citing increased conviction in the company’s recent acquisition of Verona Pharma.

Halozyme Therapeutics HALO has outperformed the market over the past 15 years by 2.0% on an annualized basis producing an average annual return of 14.27%. Currently, Halozyme Therapeutics has a ...

Merck MRK recently launched two late-stage clinical studies to evaluate MK-8527, its investigational once-monthly oral pill for HIV pre-exposure prophylaxis (PrEP). The EXPrESSIVE-11 study, which ...

Principal Financial Group Inc. grew its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 1.0% in the 1st quarter, according to its most recent disclosure with the Securities ...

Merck & Co., Inc. (NYSE: MRK) is one of the Most Undervalued High Quality Stocks to Buy According to Hedge Funds. On July 10, Morgan Stanley analyst Terence Flynn lowered the firm’s price target ...

Review the current Merck & Co Inc (MRK:XNYS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if MRK is the best investment for you.